Please wait
Healthcare · Diagnostics & Research · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
₦336T
31.0%
32.25
Current price
₦907,500.00
0.0% todayUpdated 51 min ago
Open
₦899,985.00
Previous close
₦907,500.00
Day range
₦892,215.00 – ₦909,315.00
Volume
N/A
32.2x P/E
Awaiting filing
31.0% yield
65/100 measured
Moderate liquidity
TMO has a positive bias over 30 days and positive bias over one year.
7-day forecast is free
You can use the full 7-day forecast on the free plan. Upgrade to Pro to unlock the 30-day and 1-year views.
Expected move
+2.60%
Expected price
₦931,125.00
Lower path
₦890,760.00
Upper path
₦971,490.00
Confidence
Whisone is bullish because fundamentals are solid at 72/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
₦2.6T
TTM (2026-06-30)
ROE
13.5%
Return on equity
ROA
5.1%
Return on assets
Debt / equity
0.81
Lower is usually safer.
P/B ratio
4.25
Useful for book value support.
Dividend yield
31.0%
Current income signal.
84/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦927,315.00
Analyst view
Buy
Analyst target
₦947,134.65
Forecast refresh
Updated 51 min ago
Quality score
70
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
₦585.00
2024-12-13
Payment: TBA | Qualification: 2024-12-13 | Yield at declaration: N/A
₦585.00
2024-09-13
Payment: TBA | Qualification: 2024-09-13 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+13.3% across the latest saved price window.
Volatility
Moderate
Beta is 0.85. Price sensitivity is broadly around the market range.
52-week position
81% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
q1_2026_gdp_growth
TMO may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
local manufacturing / import substitution
TMO may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
TMO may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
TMO may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
TMO may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
TMO may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
TMO may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
TMO may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
TMO
Thermo Fisher Scientific Inc.
Price: ₦907,500.00
P/E: 32.249466
Yield: 31.0%
ABBV
AbbVie Inc.
Price: ₦375,135.00
P/E: 70.44788
Yield: 2.8%
ABT
Abbott Laboratories
Price: ₦164,580.00
P/E: 35.62338
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: ₦259,432.50
P/E: 30.026909
Yield: 0.0%
Industry
Diagnostics & Research
Employees
125000
Exchange
NYQ
Ticker
TMO
